Hohimer Wealth Management
SMMT icon

Hohimer Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Hohimer Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.47M Buy
441,650
+102,550
+30% +$1.53M 0.72% 21
2026
Q2 		$4.94M Buy
+339,100
New +$6.01M 0.49% 49

Other funds holding SMMT

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Griffin Asset Management
Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Wealth Management Partners
Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Hohimer Wealth Management's SMMT Position: Q3 2026 in Review

Hohimer Wealth Management increased its Summit Therapeutics (SMMT) stake by 30% in Q3 2026, buying an estimated $1.53M and bringing the position to 441,650 shares worth $7.47M. The position accounts for 0.72% of the portfolio, ranked #21.

Hohimer Wealth Management first reported a position in SMMT in Q2 2026 and has held it in 2 quarters since. 93 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Hohimer Wealth Management held 441,650 shares of Summit Therapeutics worth $7.47M as of Q3 2026.
  • Hohimer Wealth Management bought 102,550 Summit Therapeutics shares in Q3 2026, an estimated $1.53M.
  • Summit Therapeutics made up 0.72% of Hohimer Wealth Management's portfolio in Q3 2026, its #21 holding.
  • Hohimer Wealth Management first reported a position in Summit Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 93 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Hohimer Wealth Management's 13F filing for Q3 2026, filed 2 Nov 2026.